SCHEMBL3403482

SCHEMBL3403482

CCOC(=O)c1sc(Cl)nc1-c1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
CDC7 O00311 7/20 0.49
DBF4 Q9UBU7 7/20 0.49
ALDH1A1 P00352 2/20 0.49
HSD17B10 Q99714 2/20 0.49
HPGD P15428 1/20 0.47
DHODH Q02127 5/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 2/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18236334 0.85 ALDH1A1 (0.69) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL1505433 0.84 LMNA (0.48) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL3406836 0.84 CDC7 (0.48) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL16037691 0.83 CDC7 (0.71) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL510314 0.82 CDC7 (0.62) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL3399807 0.82 CDC7 (0.51) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL3893108 0.82 ALDH1A1 (0.71) CDC7DBF4ALDH1A1HSD17B10HPGD
SCHEMBL15993345 0.81 DHODH (0.58) LMNAHPGDDHODHKMT2AMEN1
SCHEMBL509728 0.81 LMNA (0.46) LMNACDC7DBF4ALDH1A1HSD17B10
SCHEMBL11279731 0.80 CDC7 (0.69) CDC7DBF4ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-A1 PIPERIDINE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR LMNA 2265/4885CDC7 4571/4885DBF4 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.